Similar articles

• Central nervous system drug development, basic, and clinical research: thinking outside the box.

  Klein DF, Glick ID, Shader RI. Klein DF, et al. J Clin Psychopharmacol. 2011 Oct;31(5):553-4. doi: 10.1097/JCP.0b013e3182305656. J Clin Psychopharmacol. 2011. PMID: 21869701 No abstract available.
• Is pharma running out of brainy ideas?

  Miller G. Miller G. Science. 2010 Jul 30;329(5991):502-4. doi: 10.1126/science.329.5991.502. Science. 2010. PMID: 20671165 No abstract available.
• Role of pharmacogenetics in the use of CNS drugs: from drug pipeline to primary care?

  Hopkins MM, Martin PA. Hopkins MM, et al. Expert Rev Neurother. 2006 Dec;6(12):1765-7. doi: 10.1586/14737175.6.12.1765. Expert Rev Neurother. 2006. PMID: 17181421 Review. No abstract available.
• Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.

  Dawson GR, Craig KJ, Dourish CT. Dawson GR, et al. Biochem Pharmacol. 2011 Jun 15;81(12):1435-41. doi: 10.1016/j.bcp.2011.03.013. Epub 2011 Apr 1. Biochem Pharmacol. 2011. PMID: 21440531 Review.
• Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine. Interview by Steve Carney.

  Corr PB. Corr PB. Drug Discov Today. 2005 Aug 1;10(15):1017-20. doi: 10.1016/S1359-6446(05)03534-8. Drug Discov Today. 2005. PMID: 16055016 No abstract available.